Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Sagar Koduri, MD PhD, Adam C. Wang, B.S., Mette Ishoey, PhD, Joshiawa Paulk, Xiaoxi Liu, PhD, Isaac Harris, PhD, Jennifer Endress, B.S., Benjamin L. Lampson, MD PhD, Christopher J. Ott, PhD, James Bradner, MD, Jeffrey A. Medin, PhD, Sara J Buhrlage, PhD, William Kaelin, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-141558

Published: 2020

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

Greg D Whitehill, BS, Alicia Chivers, MS, Bryan Danielson, PhD, Julien SR Tessier, MS, Gabriela Hernandez Duran, Gabrielle L Bender, BS, Douglas W. Sborov, MD MSc, Craig C Hofmeister, MDMPH, James Bradner, MD, Teru Hideshima, MD PhD, Kenneth C Anderson, MD, Gullu Gorgun, PhD

Blood (2017) 130 (Supplement 1): 4422.

https://doi.org/10.1182/blood.V130.Suppl_1.4422.4422

Published: 2017

Journal Articles

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, BS, Mehmet Kemal Samur, PhD, Raphael Szalat, MD, Christopher J. Ott, PhD, Charles Epstein, Richard A. Young, PhD, James Bradner, MD, Kenneth C Anderson, MD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 64.

https://doi.org/10.1182/blood.V130.Suppl_1.64.64

Published: 2017

Journal Articles

Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Masood Shammas, PhD, Vassilis L. Souliotis, Weihua Song, MD, Jagannath Pal, MBBS, PhD, Puru Nanjappa, MS, Naim Rashid, PhD, Kenneth C. Anderson, MD, Meletios A. Dimopoulos, MD, James Bradner, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3398.

https://doi.org/10.1182/blood.V124.21.3398.3398

Published: 2014

Journal Articles

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Santhana G. T. Devaraj, PhD, Warren Fiskus, PhD, Bhavin Shah, Sunil Sharma, Jun Qi, PhD, Baohua Sun, MD PhD, Saikat Saha, PhD, Swaminathan Padmanabhan Iyer, MD, Youli Zu, MD PhD, James Bradner, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 3534.

https://doi.org/10.1182/blood.V124.21.3534.3534

Published: 2014

Journal Articles

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Bhavin Shah, Jun Qi, PhD, Santhana G. T. Devaraj, PhD, Swaminathan Padmanabhan Iyer, MD, Sunil Sharma, James Bradner, MD, Youli Zu, MD PhD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 918.

https://doi.org/10.1182/blood.V124.21.918.918

Published: 2014

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Dan T. Vogl, MD, MSCE, Edward A. Stadtmauer, MD, James Bradner, MD, Lisa Davis, PharmD, Thomas M. Paul, Emma C. Scott, MD, Charles W. Nichols, MD, David L. Porter, MD, Martin Carroll, MD, Janeen Kaplan, Gayle Mallon, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Ravi K. Amaravadi, MD

Blood (2011) 118 (21): 1869.

https://doi.org/10.1182/blood.V118.21.1869.1869

Published: 2011

Journal Articles

Regulation of Histone Deacetylase in Waldenström Macroglobulinemia

Xiaoying Jia, Aldo M. Roccaro, MD, PhD, Abdel Kareem Azab, PhD, Hai T. Ngo, Antonio Sacco, Molly R. Melhem, Feda Azab, Judith Runnels, PhD, Nicolas Burwick, MD, Phong Quang, Emanuel N. Husu, Xavier Leleu, MD, PhD, Kenneth C. Anderson, MD, James Bradner, MD, PhD, Irene M. Ghobrial, MD

Blood (2008) 112 (11): 2617.

https://doi.org/10.1182/blood.V112.11.2617.2617

Published: 2008

Journal Articles

Common Gene Deletions and Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation.

James Bradner, MD

Blood (2007) 110 (11): 37.

https://doi.org/10.1182/blood.V110.11.37.37

Published: 2007

Journal Articles

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

James Bradner, MD, Edward Greenberg, B.S., Sridevi Ponduru, M.D., Vishal Patel, B.S., Stuart Schreiber, Ph.D., Benjamin Rich, Ph.D., Ralph Mazitschek, Ph.D.

Blood (2007) 110 (11): 800.

https://doi.org/10.1182/blood.V110.11.800.800

Published: 2007

Journal Articles

Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.

James Bradner, MD, John Paul Shen, BS, Edward Greenberg, BS, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD, Stuart L. Schreiber, PhD

Blood (2005) 106 (11): 2471.

https://doi.org/10.1182/blood.V106.11.2471.2471

Published: 2005

NARROW

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Regulation of Histone Deacetylase in Waldenström Macroglobulinemia

Common Gene Deletions and Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation.

A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only